Biocon Biologics’ Bengaluru unit gets VAI classification by US FDA
This relates to the cGMP inspection conducted by the agency between February 20-28, 2024
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Biocon Biologics
Biocon and Dr Reddy’s featured in Science Magazine’s Top Employers List
This year’s ranking is based on a comprehensive web-based survey of about 6,400 respondents
Biocon Biologics report explores pathways to increase biosimilar adoption in low- and middle-income…
Biocon Biologics' study identifies six policy recommendations to improve access to biosimilars in LMICs, addressing healthcare…
Biocon Biologics refinances $ 1.1 bn long-term debt through USD bonds and new syndicated facility
The Bonds are expected to be rated BB by both S&P and Fitch and will be listed on the Singapore Stock Exchange
Biocon Biologics announces new dermatology data to be presented at EADV Congress 2024
Switching between adalimumab and adalimumab-fkjp in Phase 3 study in patients with chronic plaque psoriasis supports…
Biocon Biologics finalises agreement for Bmab 1200 market entry in Europe, UK, Canada, and Japan
Patent dispute settlement with Janssen clears path for biosimilar to Stelara in key global markets
Budget 2024-25 prioritises R&D, education and business for MSMEs
Industry stakeholders appreciate the efforts made towards increasing employment, skill-building and implementation of various…
EMA approves Biocon’s new mAbs facility in India
EMA also renews GMP certifications for Biocon’s India and Malaysia sites
Biocon Biologics obtains USFDA approval for biosimilar Aflibercept
Yesafili enters U.S. market to treat ophthalmology conditions
Biocon Biologics sells branded formulations biz to Eris Lifesciences for INR12.42 bn
Includes portfolio of metabolics, oncology, and critical care products in India and a 10-year supply agreement with Eris